穿孔素1(PRF1)活性蛋白

Active Perforin 1 (PRF1)

FLH2; HPLH2; P1; PFP; Pore Forming Protein; Cytolysin; Lymphocyte pore-forming protein

  • 穿孔素1(PRF1)活性蛋白 产品包装(模拟)
  • 穿孔素1(PRF1)活性蛋白 产品包装(模拟)
  • 穿孔素1(PRF1)活性蛋白 Figure . Gene Sequencing (extract)
  • APB317Hu01.png Figure. SDS-PAGE
  • 穿孔素1(PRF1)活性蛋白 Figure. Western Blot
  • Certificate 通过ISO 9001、ISO 13485质量体系认证

活性实验

Figure. The binding activity of PRF1 with CRT.
Perforin 1 (PRF1) is a pore forming cytolytic protein found in the granules of cytotoxic T lymphocytes (CTLs) and NK cells. Upon degranulation, perforin binds to the target cell's plasma membrane, and oligomerises in a Ca2 dependent manner to form pores on the target cell. The pore formed allows for the passive diffusion of a family of pro-apoptotic proteases, known as the granzymes, into the target cell. Besides, Calreticulin (CRT) has been identified as an interactor of PRF1, thus a binding ELISA assay was conducted to detect the interaction of recombinant human PRF1 and recombinant human CRT. Briefly, PRF1 were diluted serially in PBS, with 0.01% BSA (pH 7.4). Duplicate samples of 100μL were then transferred to CRT-coated microtiter wells and incubated for 2h at 37℃. Wells were washed with PBST and incubated for 1h with anti-PRF1 pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 3 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50µL stop solution to the wells and read at 450nm immediately. The binding activity of PRF1 and CRT was shown in Figure 1, and this effect was in a dose dependent manner.

Figure. Hemolysis activity of recombinant human PRF1.
The activity of recombinant PRF1 was measured by lysis of erythrocytes using a hemolysis assay. A general procedure is as fllows: two-fold dilute the recombinant human PRF1 with 0.9% NaCl, add 50μL a serial dilution of PRF1, 10μL 0.1M CaCl2 to each well, then add 50μL 0.25% rabbit erythrocyte (RaE) to each well and mixed gently. Add 10μL 0.9% NaCl to reaplace CaCl2 in control wells. The plate is incubated for 20 hours at 37℃, 5% CO2. The results are shown in Figure 2. It was obvious that the minimal effective concentration of PRF1 is 12.5μg/mL.
(A) 0.25% RaE tread with 12.5μg/mL PRF1 for 20h;
(B) Negative control (0.25% RaE tread with 12.5ug/mL PRF1) without CaCl2.

用法

Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

储存

避免反复冻融。2-8°C不超过一个月,-80°C不超过12个月。

稳定性

热稳定性以损失率显示。损失率是由加速降解试验决定,具体方法如下:在37°C孵育48小时,没有显著的降解或者沉淀产生。保质期内,在适当的条件下存储,损失率低于5%。

相关产品

编号 适用物种:Homo sapiens (Human,人) 应用(仅供研究使用,不用于临床诊断!)
RPB317Hu02 穿孔素1(PRF1)重组蛋白 Positive Control; Immunogen; SDS-PAGE; WB.
APB317Hu01 穿孔素1(PRF1)活性蛋白 Cell culture; Activity Assays.
RPB317Hu01 穿孔素1(PRF1)重组蛋白 Positive Control; Immunogen; SDS-PAGE; WB.
APB317Hu02 穿孔素1(PRF1)活性蛋白 Cell culture; Activity Assays.
PAB317Hu01 穿孔素1(PRF1)多克隆抗体 WB; IHC; ICC; IP.
LAB317Hu81 穿孔素1(PRF1)多克隆抗体(异硫氰酸荧光素标记) WB; IHC; ICC; IF.
LAB317Hu71 穿孔素1(PRF1)多克隆抗体(生物素标记) WB; IHC; ICC.
MAB317Hu22 穿孔素1(PRF1)单克隆抗体 WB; IHC; ICC; IP.
MAB317Hu21 穿孔素1(PRF1)单克隆抗体 WB; IHC; ICC; IP.
SEB317Hu 穿孔素1(PRF1)检测试剂盒(酶联免疫吸附试验法) Enzyme-linked immunosorbent assay for Antigen Detection.
LMB317Hu 穿孔素1(PRF1)等多因子检测试剂盒(流式荧光发光法) FLIA Kit for Antigen Detection.

参考文献

杂志 参考文献
Diagnostic Microbiology and Infectious Disease Granzyme B as a diagnostic marker of tuberculosis in patients with and without HIV coinfection [Pubmed:26915636]
FASEB JOURNAL The immunoregulatory effects of CD8 T-cell–derived perforin on diet-induced nonalcoholic steatohepatitis [Pubmed: 30951375]
Theranostics A novel Granzyme B nanoparticle delivery system simulates immune cell functions for suppression of solid tumors [Pubmed: 31695790]
Mol Immunol CD317 mediates immunocytolysis resistance by RICH2/cytoskeleton-dependent membrane protection [Pubmed: 33223223]
INVESTIGATIONAL NEW DRUGS Dual-function chimeric antigen receptor T cells targeting c-Met and PD-1 exhibit potent anti-tumor efficacy in solid tumors [Pubmed: 32772342]
Am J Transl Res Combined treatment with epigenetic agents enhances anti-tumor activity of T cells by upregulating the ACRBP expression in hepatocellular carcinoma [34377237]
Nat Biomed Eng Cancer-cell stiffening via cholesterol depletion enhances adoptive T-cell immunotherapy [34873307]
J Exp Med Single-cell immune profiling reveals functional diversity of T cells in tuberculous pleural effusion [Pubmed:35061012]
留言咨询